Primary Outcomes
Measure: Changes from baseline in abbreviated physical examination
Time: Days 1-2
Measure: Changes from baseline in clinical safety laboratory values
Time: From Day 2 up to Day 121
Measure: Changes from baseline in Electrocardiogram (ECG) parameters
Time: 15 mins after infusion
Measure: Changes from baseline in Electrocardiogram (ECG) parameters
Time: 24 hrs after infusion
Measure: Changes from baseline in symptom-directed physical examination
Time: From Day 1 up to Day 121
Measure: Changes from baseline in vital signs
Time: From Day 1 up to Day 121
Measure: The incidence of Adverse Events
Time: From Day 1 up to Day 121
Measure: The incidence of treatment-emergent Serious Adverse Events
Time: From Day 1 up to Day 121
Measure: The severity of Adverse Events assessed by toxicity grading criteria
Time: From Day 1 up to Day 121
Measure: The severity of treatment-emergent Serious Adverse Events assessed by toxicity grading criteria
Time: From Day 1 up to Day 121
Measure: The type of treatment-emergent Serious Adverse Events
Time: From Day 1 up to Day 121
Secondary Outcomes
Measure: AUC for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: AUC for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: AUC(0-infinity) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: AUC(0-infinity) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: CL for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: CL for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: CMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: CMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: K(e) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: K(e) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: t(1/2) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: t(1/2) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays
Time: Day 121
Measure: The change from baseline of antibodies against REGN3048 and REGN3051 (anti-drug antibodies, ADA), as measured in serum using validated bridging assays
Time: Day 57
Measure: TMAX for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: TMAX for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: V(ss) for each dose of REGN3048 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121
Measure: V(ss) for each dose of REGN3051 measured using validated Enzyme Linked Immunosorbent Assays (ELISAs)
Time: From Day 1 up to Day 121